Evidence map›Paper›PMID 31765423›Full record

ArticlePloS one2019

Metastasis risk prediction model in osteosarcoma using metabolic imaging phenotypes: A multivariable radiomics model.

Heesoon Sheen, Wook Kim, Byung Hyun Byun, Chang-Bae Kong, Won Seok Song, Wan Hyeong Cho, Ilhan Lim, Sang Moo Lim, Sang-Keun Woo

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. [Artificial intelligence in orthopaedic oncology].Orthopadie (Heidelberg, Germany) · 2026
    Review
  5. Review
  6. Artificial Intelligence Applications in Musculoskeletal Imaging.Current reviews in musculoskeletal medicine · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Heesoon SheenDivision of applied RI, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.
Wook KimDivision of applied RI, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.
Byung Hyun ByunDepartments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.
Chang-Bae KongDepartment of Orthopedic Surgery, Korea Institute of Radiology and Medical Sciences, Seoul, Republic of Korea.
Won Seok SongDepartment of Orthopedic Surgery, Korea Institute of Radiology and Medical Sciences, Seoul, Republic of Korea.
Wan Hyeong ChoDepartment of Orthopedic Surgery, Korea Institute of Radiology and Medical Sciences, Seoul, Republic of Korea.
Ilhan LimDepartments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.
Sang Moo LimDepartments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.
Sang-Keun WooDivision of applied RI, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Republic of Korea.ORCID 0000-0002-6728-8876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is the most common primary bone tumor affecting humans and it has extreme heterogeneity. Despite modern therapy, it recurs in approximately 30-40% of patients initially diagnosed with no metastatic disease, with the long-term survival rates of patients with recurrent OS being generally 20%. Thus, early prediction of metastases in OS management plans is crucial for better-adapted treatments and survival rates. In this study, a radiomics model for metastasis risk prediction in OS was developed and evaluated using metabolic imaging phenotypes. METHODS AND

findingsThe subjects were eighty-three patients with OS, and all were treated with surgery and chemotherapy for local control. All patients underwent a pretreatment 18F-FDG-PET scan. Forty-five features were extracted from the tumor region. The incorporation of features into multivariable models was performed using logistic regression. The multivariable modeling strategy involved cross validation in the following four steps leading to final prediction model construction: (1) feature set reduction and selection; (2) model coefficients computation through train and validation processing; and (3) prediction performance estimation. The multivariable logistic regression model was developed using two radiomics features, SUVmax and GLZLM-SZLGE. The trained and validated multivariable logistic model based on probability of endpoint (P) = 1/ (1+exp (-Z)) was Z = -1.23 + 1.53*SUVmax + 1.68*GLZLM-SZLGE with significant p-values (SUVmax: 0.0462 and GLZLM_SZLGE: 0.0154). The final multivariable logistic model achieved an area under the curve (AUC) receiver operating characteristics (ROC) curve of 0.80, a sensitivity of 0.66, and a specificity of 0.88 in cross validation.

conclusionsThe SUVmax and GLZLM-SZLGE from metabolic imaging phenotypes are independent predictors of metastasis risk assessment. They show the association between 18F-FDG-PET and metastatic colonization knowledge. The multivariable model developed using them could improve patient outcomes by allowing aggressive treatment in patients with high metastasis risk.

Indexed as

AdultBone NeoplasmsFemaleFluorodeoxyglucose F18HumansMaleNeoplasm MetastasisOsteosarcomaPhenotypePositron-Emission TomographyPrognosisRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID31765423
PMCPMC6876771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.